secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-07-27T12:00:16+00:00
Accession:  0001193125-26-316916
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna signs commercial manufacturing deal with ElevateBio for miv-cel; BLA on track for Q4 2026
--------------------------------------------------------------------------------

- Agreement covers U.S. commercial and global clinical supply of miv-cel, replacing prior clinical deal.
- Supports potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
- Rolling BLA submission for miv-cel in SPS remains on track for Q4 2026.
- ElevateBio achieved >98% clinical manufacturing success rate for miv-cel.
- Initial five-year term with automatic renewals; minimum purchase commitments and annual PPI-based price adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/0001193125-26-316916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/kytx-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer